Company intelligence / Profile preview

Civic

Petersburg, Virginia, United States

Ownership: Private
Employees: ~201
Development stage: Other

Overview

Civica commercializes 80+ essential generic drugs to over 1500 U.S. hospitals, serving tens of millions of patients, and is launching biosimilar insulin to reduce patient cost and address shortages

Therapeutic areas: CardiovascularEndocrinologyInfectious DiseasesNeurologyOther
Modalities: Small moleculeBiologicBiosimilar (Insulin)Sterile injectable medications
Industry: Biotech

Partnerships

GeneSys Biologics (biosimilar insulin)Biocon Biologics (insulin ecosystem)

Beyond the preview

Go deeper on Civic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Civic.

Explore the full profile